Jinghua Pharmaceutical Group (002349) Stock Overview
Engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
002349 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Jinghua Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.15 |
| 52 Week High | CN¥9.34 |
| 52 Week Low | CN¥6.35 |
| Beta | 0.067 |
| 1 Month Change | -4.92% |
| 3 Month Change | -2.99% |
| 1 Year Change | -10.63% |
| 3 Year Change | -35.06% |
| 5 Year Change | 34.65% |
| Change since IPO | 113.22% |
Recent News & Updates
Recent updates
There's No Escaping Jinghua Pharmaceutical Group Co., Ltd.'s (SZSE:002349) Muted Earnings
Jan 14
Jinghua Pharmaceutical Group (SZSE:002349) Has A Rock Solid Balance Sheet
Dec 18Some Shareholders Feeling Restless Over Jinghua Pharmaceutical Group Co., Ltd.'s (SZSE:002349) P/E Ratio
Sep 26Jinghua Pharmaceutical Group (SZSE:002349) Could Easily Take On More Debt
Aug 07Jinghua Pharmaceutical Group's (SZSE:002349) Upcoming Dividend Will Be Larger Than Last Year's
Jun 07Shareholder Returns
| 002349 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 1.8% |
| 1Y | -10.6% | 17.6% | 24.1% |
Return vs Industry: 002349 underperformed the CN Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: 002349 underperformed the CN Market which returned 24.1% over the past year.
Price Volatility
| 002349 volatility | |
|---|---|
| 002349 Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 002349 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002349's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 1,490 | Jian Cheng | www.jinghuapharm.com |
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd.
Jinghua Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 002349 fundamental statistics | |
|---|---|
| Market cap | CN¥5.93b |
| Earnings (TTM) | CN¥207.86m |
| Revenue (TTM) | CN¥1.41b |
Is 002349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002349 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.41b |
| Cost of Revenue | CN¥707.84m |
| Gross Profit | CN¥705.36m |
| Other Expenses | CN¥497.49m |
| Earnings | CN¥207.86m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 30, 2025
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 49.91% |
| Net Profit Margin | 14.71% |
| Debt/Equity Ratio | 0.0003% |
How did 002349 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 20:46 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jinghua Pharmaceutical Group Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wenxin Yu | China Investment Securities |
| Ye Hui Yang | Huatai Research |
| Wen Qing Wei | Shenwan Hongyuan Securities |